Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine